Cytokinetics, Incorporated (CYTK)

Market Cap	7.61B +55.1%
Revenue (ttm)	88.04M +376.6%
Net Income	-784.96M
EPS	-6.54
Shares Out	122.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,432,026
Open	62.08
Previous Close	62.63
Day's Range	61.91 - 62.99
52-Week Range	29.31 - 70.98
Beta	0.55
Analysts	Strong Buy
Price Target	86.00 (+38.22%)
Earnings Date	Feb 24, 2026

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle tropo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2004
• Employees: 498
• Stock Exchange: NASDAQ
• Ticker Symbol: CYTK
• Website: https://www.cytokinetics.com

Financial Performance

In 2025, Cytokinetics's revenue was $88.04 million, an increase of 376.56% compared to the previous year's $18.47 million. Losses were -$784.96 million, 33.2% more than in 2024.

Analyst Summary

According to 18 analysts, the average rating for CYTK stock is "Strong Buy." The 12-month stock price target is $86.0, which is an increase of 38.22% from the latest price.

Price Target

$86.0

(38.22% upside)

Analyst Consensus: Strong Buy